Metformin versus placebo in obese pregnant women without diabetes mellitus by Syngelaki, A. et al.
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 374;5 nejm.org February 4, 2016434
From the Harris Birthright Research Cen-
tre for Fetal Medicine, King’s College 
Hospital (A.S., K.H.N., R.A., R.K., A.P.), 
and the Departments of Endocrinology 
(J.B., S.H.) and Maternal Medicine (H.S.), 
Epsom and St. Helier University Hospi-
tals NHS Trust, London, and the Depart-
ment of Fetal Medicine, Medway Mari-
time Hospital, Gillingham, Kent (R.A.) 
— all in the United Kingdom. Address 
reprint requests to Dr. Shehata at the De-
partment of Maternal Medicine, Epsom 
and St. Helier University Hospitals NHS 
Trust, London SM5 1AA, United King-
dom, or at  hassan . shehata@ nhs . net.
N Engl J Med 2016;374:434-43.
DOI: 10.1056/NEJMoa1509819
Copyright © 2016 Massachusetts Medical Society.
BACKGROUND
Obesity is associated with an increased risk of adverse pregnancy outcomes. 
Lifestyle-intervention studies have not shown improved outcomes. Metformin im-
proves insulin sensitivity and in pregnant patients with gestational diabetes it 
leads to less weight gain than occurs in those who do not take metformin.
METHODS
In this double-blind, placebo-controlled trial, we randomly assigned pregnant women 
without diabetes who had a body-mass index (BMI; the weight in kilograms di-
vided by the square of the height in meters) of more than 35 to receive metformin, 
at a dose of 3.0 g per day, or placebo (225 women in each group) from 12 to 18 weeks 
of gestation until delivery. The BMI was calculated at the time of study entry (12 
to 18 weeks of gestation). The primary outcome was a reduction in the median 
neonatal birth-weight z score by 0.3 SD (equivalent to a 50% reduction, from 20% 
to 10%, in the incidence of large-for-gestational-age neonates). Secondary out-
comes included maternal gestational weight gain and the incidence of gestational 
diabetes and of preeclampsia, as well as the incidence of adverse neonatal out-
comes. Randomization was performed with the use of computer-generated random 
numbers. The analysis was performed according to the intention-to-treat principle.
RESULTS
A total of 50 women withdrew consent during the trial, which left 202 women in 
the metformin group and 198 in the placebo group. There was no significant 
between-group difference in the median neonatal birth-weight z score (0.05 in the 
metformin group [interquartile range, −0.71 to 0.92] and 0.17 in the placebo group 
[interquartile range, −0.62 to 0.89], P = 0.66). The median maternal gestational 
weight gain was lower in the metformin group than in the placebo group (4.6 kg 
[interquartile range, 1.3 to 7.2] vs. 6.3 kg [interquartile range, 2.9 to 9.2], P<0.001), 
as was the incidence of preeclampsia (3.0% vs. 11.3%; odds ratio, 0.24; 95% con-
fidence interval, 0.10 to 0.61; P = 0.001). The incidence of side effects was higher 
in the metformin group than in the placebo group. There were no significant 
between-group differences in the incidence of gestational diabetes, large-for-ges-
tational-age neonates, or adverse neonatal outcomes.
CONCLUSIONS
Among women without diabetes who had a BMI of more than 35, the antenatal 
administration of metformin reduced maternal weight gain but not neonatal birth 
weight. (Funded by the Fetal Medicine Foundation; ClinicalTrials.gov number, 
NCT01273584; EudraCT number, 2008-005892-83.)
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The prevalence of obesity is increas-ing both in developed countries and in developing countries, and obesity is con-
sidered to be a global pandemic.1 An estimated 
one fifth of pregnant women in the United 
Kingdom and one third of those in the United 
States are obese.2,3 Obesity during pregnancy is 
associated with an increased risk of adverse 
short-term and long-term consequences for both 
mother and baby.4-11 Attempts at reducing the 
incidence of pregnancy complications associated 
with obesity have focused on dietary and life-
style interventions, but these have generally been 
unsuccessful.12-17
An alternative strategy is the use of metfor-
min, which reduces insulin resistance. Metfor-
min has been used extensively in the treatment 
of gestational diabetes mellitus,18 and there has 
been no evidence of an increase in the incidence 
of birth defects associated with its use.19 Hyper-
glycemia and increased insulin resistance occur 
with obesity20 and may explain the association 
between obesity and fetal macrosomia, as well 
as other pregnancy complications.21 Studies in-
volving women with gestational diabetes melli-
tus have shown that metformin reduces gesta-
tional weight gain.18,22 The Metformin in Obese 
Nondiabetic Pregnant Women (MOP) trial was 
designed to test the hypothesis that metformin, 
as compared with placebo, would be associated 
with a lower median neonatal birth-weight z score 
when administered to pregnant women without 
diabetes who had a body-mass index (BMI; the 
weight in kilograms divided by the square of the 
height in meters) of more than 35.
Me thods
Trial Design and Participants
In this study, we randomly assigned women 
without diabetes who had a BMI of more than 
35 and were at 12 to 18 weeks of gestation with 
a singleton fetus to receive metformin or place-
bo. Participants were from three National Health 
Service (NHS) maternity hospitals in the United 
Kingdom (King’s College Hospital, London; 
Medway Maritime Hospital, Kent; and Epsom 
and St. Helier University Hospitals NHS Trust, 
London). In these hospitals, all women receiving 
pregnancy care are offered an ultrasonographic 
examination at 11 to 13 weeks of gestation as 
part of combined screening for trisomy 21. Preg-
nancy dating was based on the measurement of 
the fetal crown–rump length at that scan. The 
BMI was calculated at the time of study entry 
(12 to 18 weeks of gestation). The demographic 
characteristics of the mothers and the medical 
history were recorded in a database.
Exclusion criteria were a maternal age of less 
than 18 years; a major fetal defect observed on 
the scan performed at 11 to 13 weeks of gesta-
tion; a history of gestational diabetes mellitus; 
kidney, liver, or heart failure; a serious medical 
condition; hyperemesis gravidarum; treatment 
with metformin at the time of screening; known 
sensitivity to metformin; and miscarriage before 
randomization. Potential trial participants were 
given written information about the trial; they 
then had at least 24 hours to consider participa-
tion. All the women who agreed to participate in 
the trial provided written informed consent.
Ethical approval for the study was obtained 
from the London–Surrey Borders Research Eth-
ics committee, and clinical trial authorization 
was obtained from the Medicines and Healthcare 
Products Regulatory Agency. The study protocol, 
including the statistical analysis plan, is avail-
able with the full text of this article at NEJM.org.
Two of the authors wrote the first draft of the 
manuscript, and all the authors contributed to 
its revision and made the decision to submit the 
manuscript for publication. Study funding was 
provided by the Fetal Medicine Foundation, 
which had no role in the study design, the col-
lection, analysis, or interpretation of the data, or 
the writing of the report. Quality control of 
screening and verification of adherence to proto-
cols at the various centers were performed on a 
regular basis by the trial coordinators.
Randomization and Study-Group Assignments
Eligible women were randomly assigned, in a 1:1 
ratio, with the use of computer-generated random 
numbers, to receive either metformin or placebo. 
In the random-sequence generation there were no 
restrictions, such as block size or stratification 
according to study site. The appearance, size, 
weight, and taste of the placebo tablets were 
identical to those of the metformin tablets; both 
were purchased at full cost from University Col-
lege London Hospitals NHS Foundation Trust.
The women in each group were prescribed 
metformin or placebo on their first visit after 
randomization. All the women received standard-
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ized personal advice on healthy eating, with an 
emphasis on low-glycemic-index foods, and were 
encouraged to exercise for 30 minutes each day.
The metformin or placebo was given with 
meals; metformin was initiated at a daily dose of 
1.0 g in week 1, and the dose was increased by 
0.5 g per week to a maximum dose of 3.0 g in 
week 5. Women with serious side effects while 
taking the full dose were asked to continue tak-
ing the maximum tolerated dose. The study regi-
men was stopped if fetal growth restriction — 
defined by an estimated fetal weight lower than 
the fifth percentile and abnormal results of fetal 
Doppler studies — was detected.
Follow-up Visits
Follow-up visits were scheduled at intervals of 4 
to 6 weeks for prescription of metformin or pla-
cebo and for maternal assessment, including 
measurement of weight and blood pressure and 
urinalysis for proteins and ketones. We assessed 
adherence to taking metformin or placebo by 
counting the tablets returned by the patients at 
each visit; if during a given visit a patient forgot 
to return the tablets, we relied on verbal report 
and on the results of previous and subsequent 
visits. Adherence was considered to be good if 
the total number of tablets consumed was at 
least 50% of the total number prescribed and 
poor if it was less than 50%.
All the women underwent an 75-g oral glu-
cose-tolerance test (OGTT) at 28 weeks of ges-
tation; metformin or placebo was stopped for 
1 week before the date of the test. Women with 
abnormal results on the OGTT (i.e., results that 
met the World Health Organization 199923 crite-
ria for gestational diabetes mellitus) were ad-
vised to continue the assigned study regimen as 
before and to commence home glucose monitor-
ing. If target blood-glucose values were not 
achieved, insulin was added to their existing 
regimen. Women with normal OGTT results 
continued with the study regimen as before.
The clinical data of the participants were re-
corded in the study database at each visit. De-
tails regarding delivery and neonatal outcomes 
were added as soon as they became available.
Outcome Measures
The primary outcome measure was the median 
neonatal birth-weight z score (difference between 
observed and expected birth weight, with adjust-
ment for gestational age, divided by the fitted 
standard deviation). The expected birth weight, 
corrected for gestational age, was derived from 
our population of phenotypically normal neo-
nates born alive at 24 weeks of gestation or later.24
Maternal secondary outcome measures in-
cluded gestational weight gain, which was de-
fined as the difference in maternal weight be-
tween the day of randomization and the last 
antenatal visit, gestational diabetes mellitus, 
preeclampsia,25 pregnancy-induced hyperten-
sion,25 delivery by cesarean section, and postpar-
tum hemorrhage, which was defined as blood 
loss of 1 liter or more. Key secondary outcomes 
for the fetus or neonate included death before 24 
weeks of gestation, stillbirth at 24 weeks of ges-
tation or later, preterm birth before 37 weeks of 
gestation, status of being large for gestational 
age (birth weight >90th percentile, with adjust-
ment for gestational age),24 birth trauma (shoul-
der dystocia, or brachial plexus injury or fracture), 
an Apgar score of less than 7 at 5 minutes, ad-
mission to a level 2 or 3 neonatal unit, hypogly-
cemia (plasma glucose levels <46.8 mg per 
deciliter [2.6 mmol per liter] on two occasions 
≥30 minutes apart), hyperbilirubinemia requir-
ing phototherapy, and respiratory distress, which 
was defined by the need for more than 4 hours 
of respiratory support or supplemental oxygen.
Adverse Events
Patients were advised to contact their local in-
vestigator if any adverse events occurred. The 
nature, time of onset, and severity of the event, 
the treatment needed, and any relation to the 
assigned study regimen were recorded. All seri-
ous adverse events were reported to the sponsor.
Statistical Analysis
The sample-size estimation was based on our data 
from 72,013 singleton pregnancies for which rou-
tine screening was performed for trisomies at 
11 to 13 weeks of gestation. At that screening visit, 
the maternal weight and height were measured 
and the BMI was calculated. In that large popula-
tion, the neonatal birth weight was normally dis-
tributed, with a median (±SD) of 3381±563 g.
In the subgroup of pregnancies in which the 
mother’s BMI was 35 or less (67,354 women), 
the median neonatal birth weight was 3351 g, 
and the prevalence of large-for-gestational-age 
neonates was 10%. In the subgroup of pregnan-
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cies in which the mother’s BMI was more than 
35 (4659 women), the median neonatal birth 
weight was 3516 g, and the prevalence of large-
for-gestational-age neonates was 20%. There-
fore, the median birth weight in neonates whose 
mothers had a BMI of more than 35 was 0.3 SD 
(165 ÷ 563) higher than in those whose mothers 
had a BMI of 35 or less.
Since metformin is associated with less ges-
tational weight gain18,22 and since birth weight is 
related to both maternal BMI and gestational 
weight gain,10,26 we hypothesized that the use of 
metformin in women with a BMI of more than 
35 might result in a reduction in the mean neo-
natal birth weight by 0.3 SD — down to the 
value observed in neonates born to women with 
a BMI of 35 or less. We estimated that 400 pa-
tients would need to undergo randomization to 
give the study 80% power to detect such a reduc-
tion at a 5% significance level; after allowing for 
an expected withdrawal of 20%, we calculated 
that we would need to recruit 450 patients. The 
analysis was performed according to the inten-
tion-to-treat principle.
Baseline data for the mothers in the two study 
groups were summarized with the use of medi-
ans and interquartile ranges. Comparisons be-
tween groups were performed with the use of the 
Mann–Whitney U test. Univariate comparisons of 
dichotomous data were performed with the use 
of the chi-square test or Fisher’s exact test.
R esult s
Study Population
The study period was from October 2010 through 
June 2015 at Epsom and St. Helier University Hos-
pitals, from June 2013 through June 2015 at King’s 
College Hospital, and from September 2013 
through June 2015 at Medway Maritime Hospital. 
In all the hospitals, there was a 5-month gap in 
recruitment because of problems with the manu-
facture of the drugs. At Epsom and St. Helier 
University Hospitals, several periods of interrup-
tion occurred because of problems with personnel.
A total of 1071 women without diabetes who 
had a BMI of more than 35 and a singleton preg-
nancy were assessed for eligibility, but 227 were 
excluded (Fig. 1). Of the 844 eligible women, 450 
(53.3%) agreed to participate in the study. After 
randomization, 50 women (23 women in the 
metformin group and 27 in the placebo group) 
withdrew consent. Withdrawal of consent oc-
curred within 10 days after enrollment in 42 of 
the 50 cases (84%) and at 14 to 49 days in the 
remaining 8 cases.
The maternal characteristics and obstetrical 
history of the 202 participants in the metformin 
group and the 198 participants in the placebo 
group are shown in Table 1. There were no sig-
nificant between-group differences in the char-
acteristics at baseline apart from maternal age, 
which was higher in the metformin group than 
in the placebo group.
Outcome Measures
There were no significant differences between the 
metformin group and the placebo group in the 
median neonatal birth-weight z score, the inci-
dence of large-for-gestational-age neonates, or the 
incidence of adverse fetal or neonatal outcomes 
(Table 2). The median gestational weight gain in 
the mother and the incidence of preeclampsia 
were lower in the metformin group than in the 
placebo group, but there were no significant be-
tween-group differences in the other secondary 
outcomes (Table 2; and Tables S1 through S4 and 
Fig. S1 in the Supplementary Appendix, available 
at NEJM.org). In the total cohort of participants, 
there was a significant association between mater-
nal gestational weight gain and the incidence of 
preeclampsia (r = 0.17, P = 0.001).
Adverse Events
There was no significant between-group differ-
ence in the incidence of serious adverse events, 
but the incidence of side effects was higher in 
the metformin group than in the placebo group 
(Table 3, and Table S5 in the Supplementary Ap-
pendix). In response to side effects, 17.6% of the 
women stopped taking their tablets, 41.8% re-
duced the dose, and 40.6% continued with the 
full dose; there were no significant between-
group differences with regard to these decisions. 
In seven patients (two patients in the metformin 
group and five in the placebo group), the study 
regimen was stopped because of fetal growth 
restriction, as evidenced by an estimated fetal 
weight below the 5th percentile and abnormal 
fetal Doppler studies.
Adherence
The maximum tolerated daily dose of met-
formin or placebo was 3.0 g in 254 of the 400 
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women (63.5%), 2.0 or 2.5 g in 57 women 
(14.2%), and less than 2 g in 89 women (22.2%); 
the number of women taking each dose was 
used as the denominator in calculating the 
rate of adherence (Table S6 in the Supplemen-
tary Appendix). Adherence was good in 318 
women (79.5%) and poor in 82 (20.5%). The 
prevalence of good adherence was directly re-
lated to the final maximum tolerated dose of 
medication; the prevalence was 93.5% among 
women taking the full dose of 3.0 g and only 
53.3% among those who were taking less than 
2.0 g of the drug. There were no significant 
between-group differences in the degree of 
adherence.
Discussion
Our trial showed that in pregnant women with-
out diabetes who had a BMI of more than 35, the 
daily administration of metformin from 12 to 18 
weeks of gestation until delivery did not reduce 
the median neonatal birth-weight z score or the 
incidence of large-for-gestational-age neonates. 
However, metformin was associated with less 
maternal gestational weight gain and a lower 
incidence of preeclampsia than were seen with 
placebo. There was no significant difference 
between the groups in the incidence of other 
pregnancy complications or of adverse fetal or 
neonatal outcomes.
Figure 1. Screening, Randomization, and Analysis Populations.
The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.
844 Were eligible
1071 Patients without diabetes with
BMI >35  were assessed for eligibility
 227 Were excluded
6 Were <18 years of age
17 Had fetus with fetal defect
66 Had history of gestational
diabetes mellitus
18 Had medical problems
6 Had gastric bypass
68 Had hyperemesis
25 Were receiving metformin
8 Could not take metformin 
13 Had miscarriage
225 Were assigned to receive metformin 225 Were assigned to receive placebo
394 Declined to participate
202 Were included in the analysis 198 Were included in the analysis
450 Underwent randomization
23 Withdrew consent 27 Withdrew consent 
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Side effects, including nausea and vomiting, 
diarrhea, and headache, were as expected during 
gestation, but the incidence of side effects was 
significantly higher in the metformin group 
than in the placebo group. However, among the 
women with side effects, there were no signifi-
cant between-group differences with regard to 
the decision of whether to continue with the full 
dose, reduce the dose, or stop the study regi-
men. Regardless of side effects, adherence to the 
study regimen was good (≥50% of tablets taken) 
in nearly 80% of the women and did not differ 
significantly between the two groups. The rate 
of adherence was considerably higher among 
women taking the full dose of 3.0 g per day than 
among those taking less than 2.0 g per day, 
which suggests that adherence was not driven by 
the presence or absence of side effects but by the 
motivation of the patients to adhere to the de-
mands of the study.
The major strengths of our trial include the 
racially heterogeneous nature of the participat-
ing women, who had moderate-to-severe obesity 
and were selected from a screened population of 
women receiving routine pregnancy care. In ad-
dition, a high percentage of eligible women 
agreed to participate and they also had a high 
rate of adherence to the study regimen.
The study has certain limitations. It was not 
adequately powered for the secondary outcomes. 
In a screening study involving 120,492 women 
with singleton pregnancies in our population, 
the incidence of preeclampsia was 2.2%,9 and in 
the subgroup of 7152 women (5.9%) with a BMI 
of more than 35, the incidence was 5.5%. For a 
randomized trial to have 80% power to detect a 
reduction in the incidence of preeclampsia from 
5.5% to the observed 3.0% in the metformin 
group, at a 5% significance level, 2050 patients 
would need to be recruited.
We found that, among obese women, less 
gestational weight gain was associated with a 
lower prevalence of preeclampsia. This finding 
is compatible with the results of several previous 
studies that showed that the prevalence of pre-
eclampsia increased with both increasing pre-
pregnancy BMI and increasing gestational 
weight gain.9,10,26-28
Most previous studies that have investigated 
the effect of metformin on pregnancy outcome 
have involved women with the polycystic ovary 
syndrome.29-32 In four randomized, controlled 
trials, metformin or placebo was given from 5 to 
6 weeks of gestation until delivery. One trial 
involving 40 women who received metformin at 
Characteristic
Metformin 
(N = 202)
Placebo 
(N = 198)
Median maternal age (IQR) — yr 32.9 
(27.3–36.2)
30.8 
(26.6–34.4)
Median maternal weight (IQR) — kg† 104.7 
(95.7–116.2)
105.4 
(97.0–115.5)
Median maternal height (IQR) — cm 165 
(160–168)
165 
(160–169)
Median body-mass index (IQR)‡ 38.6 
(36.5–41.5)
38.4 
(36.3–41.9)
Median gestational age at randomiza-
tion (IQR) — wk
15.1 
(13.7–17.0)
14.9 
(13.6–17.3)
Race or ethnic group — no. (%)§
White 142 (70.3) 128 (64.6)
Black 50 (24.8) 55 (27.8)
South Asian 7 (3.5) 12 (6.1)
East Asian 1 (0.5) 0
Mixed 2 (1.0) 3 (1.5)
Medical history — no. (%)
Chronic hypertension 13 (6.4) 17 (8.6)
Polycystic ovary syndrome 26 (12.9) 18 (9.1)
Cigarette smoking 15 (7.4) 21 (10.6)
Conception — no. (%)
Spontaneous 197 (97.5) 194 (98.0)
Ovulation induction 2 (1.0) 3 (1.5)
In vitro fertilization 3 (1.5) 1 (0.5)
Parity — no. (%)
Nulliparous 55 (27.2) 68 (34.3)
Parous with previous preeclampsia 14 (6.9) 13 (6.6)
Parous with previous large-for- 
gestational-age neonate
39 (19.3) 31 (15.7)
*  Comparison between groups was performed with the use of the Mann–Whitney 
U test for continuous variables and the chi-square test for categorical variables. 
There were no significant (P<0.05) between-group differences in any of the 
characteristics listed here except for maternal age, which was higher in the 
metformin group than in the placebo group (P = 0.02). IQR denotes interquar-
tile range.
†  The pregnancy weight was measured at the time of study entry (12 to 18 weeks 
of gestation).
‡  The body-mass index (the weight in kilograms divided by the square of the 
height in meters) was calculated at the time of study entry (12 to 18 weeks of 
gestation).
§  Race or ethnic group was self-reported.
Table 1. Maternal Characteristics and Obstetrical History, According to Study 
Group.*
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a dose of 1.7 g per day or placebo showed that 
metformin had no significant effect on neonatal 
birth weight or on the incidence of preeclampsia 
or maternal gestational diabetes mellitus.29 
These results were confirmed by a larger study 
involving 273 women and a higher dose of met-
formin of 2.0 g per day; that study showed that 
women who received the drug had significantly 
less maternal gestational weight gain than did 
those who received placebo but that metformin 
was not associated with a significantly lower 
median neonatal birth weight or incidence of 
preeclampsia, gestational diabetes mellitus, or 
preterm birth.30 In contrast, a trial involving 40 
women showed that metformin at a dose of 1.7 g 
per day was associated with a significantly lower 
rate of preeclampsia than the rate among wom-
en who received placebo.31 Another study involv-
ing 40 women showed that metformin at a dose 
of 850 mg per day, as compared with placebo, 
had no significant effect on the incidence of 
gestational diabetes mellitus.32
One recent randomized, controlled trial, the 
Effect of Metformin on Maternal and Fetal Out-
Outcome Metformin (N = 202)
Placebo 
(N = 198)
Odds Ratio 
(95% CI) P Value
Primary outcome
Median birth-weight z score (IQR) 0.05 
(−0.71 to 0.92)
0.17 
(−0.62 to 0.89) — 0.66
Fetal or neonatal outcomes
Miscarriage — no. (%) 0 3 (1.5) — 0.12
Stillbirth — no. (%) 1 (0.5) 2 (1.0) 0.49 (0.04 to 5.42) 0.62
Neonatal death — no. (%) 0 1 (0.5) — 0.49
Live birth — no. (%) 201 (99.5) 192 (97.0) 6.28 (0.78 to 52.66) 0.12
Delivery at <37 weeks of gestation — no./total no. (%) 13/202 (6.4) 21/195 (10.8) 0.57 (0.28 to 1.17) 0.12
Median birth-weight percentile (IQR) 51.8 
(23.9 to 82.1)
56.6 
(26.8 to 81.4) — 0.66
Large for gestational age — no./total no. (%)† 34/202 (16.8) 30/195 (15.4) 1.11 (0.65 to 1.90) 0.79
Birth trauma — no. (%) 3/202 (1.5) 3/195 (1.5) 0.96 (0.19 to 4.84) 1.00
Apgar score at 5 min <7 — no. (%) 1/202 (0.5) 3/195 (1.5) 0.32 (0.03 to 3.09) 0.36
Admission to NICU — no./total no. (%) 11/202 (5.4) 14/195 (7.2) 0.74 (0.33 to 1.68) 0.47
Hypoglycemia — no./total no. (%) 9/202 (4.5) 11/195 (5.7) 0.78 (0.32 to 1.93) 0.58
Hyperbilirubinemia — no./total no. (%) 11/202 (5.4) 15/195 (7.7) 0.69 (0.31 to 1.54) 0.36
Respiratory distress syndrome — no./total no. (%) 9/202 (4.5) 13/195 (6.7) 0.65 (0.27 to 1.56) 0.33
Maternal outcomes
Median weight gain (IQR) — kg 4.6 
(1.3 to 7.2)
6.3 
(2.9 to 9.2) — <0.001
Gestational diabetes mellitus — no./total no. (%) 25/202 (12.4) 22/195 (11.3) 1.11 (0.60 to 2.04) 0.74
Preeclampsia — no./total no. (%) 6/202 (3.0) 22/195 (11.3) 0.24 (0.10 to 0.61) 0.001
Pregnancy-induced hypertension — no./total no. (%) 13/202 (6.4) 13/195 (6.7) 0.96 (0.43 to 2.13) 0.93
Delivery by cesarean section — no./total no. (%) 80/202 (39.6) 82/195 (42.1) 0.93 (0.62 to 1.38) 0.79
Postpartum hemorrhage — no./total no. (%) 19/202 (9.4) 16/195 (8.2) 1.16 (0.58 to 2.33) 0.67
*  The percentages for delivery before 37 weeks of gestation, birth trauma, Apgar score less than 7 at 5 minutes, admission to the neonatal in-
tensive care unit (NICU), hypoglycemia, hyperbilirubinemia, and the respiratory distress syndrome and all secondary maternal outcomes were 
calculated after the exclusion of three patients with miscarriage in the placebo group. Data on median birth-weight z score and percentile 
were missing for three neonates in the placebo group. The comparison between groups was performed with the use of the Mann–Whitney 
U test for continuous variables and the chi-square test for categorical variables. In view of multiple comparisons, a P value of less than 
0.0025, rather than less than 0.05, was considered to indicate statistical significance. CI denotes confidence interval.
†  Large-for-gestational-age status was defined by a neonatal weight that was higher than the 90th percentile.
Table 2. Pregnancy Outcomes, According to Study Group.*
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comes in Obese Pregnant Women (EMPOWaR) 
trial, examined the effect of metformin at a dose 
of 2.5 g per day, administered from 16 to 18 
weeks of gestation to delivery, in 449 white 
women without diabetes who had a BMI of more 
than 30.33 That study showed no significant dif-
ferences between the metformin group and the 
placebo group in the median birth weight, ma-
Category and Event
Metformin 
(N = 202)
Placebo 
(N = 198)
Fetal death
Miscarriage 0 3
Stillbirth 1 2
Fetal defect
Arachnoid cyst, diagnosed prenatally at 32 wk 1 0
Moderate unilateral hydronephrosis, diagnosed prenatally at 34 wk 0 1
Transposition of the great arteries, diagnosed postnatally 1 0
Trisomy 21, diagnosed postnatally 1 0
Fetal disease
Congenital hyperinsulinism 1 0
Fetal anemia due to Rh hemolytic disease, with delivery at 33 wk 1 0
Maternal disease
Admission for acute fatty liver at 32 wk 1 0
Admission for chest pain postnatally 0 1
Admission for dehydration at 27 wk 1 0
Admission for fibula and tibia fracture at 33 wk 1 0
Admission for gestational asthma at 30 wk 1 0
Admission for headache and neurologic symptoms at 16 wk 0 1
Admission for numbness in both legs at 32 wk 0 1
Admission for pancreatitis at 33 wk 1 0
Admission for psychosis at 37 wk 0 1
Admission for pyelonephritis at 34 wk 0 1
Admission for tachycardia at 33 wk 1 0
Scar dehiscence in woman with four previous cesarean sections, at 28 wk 0 1
Preeclampsia or fetal growth restriction
Admission for preeclampsia and subsequent preterm delivery 1 6
Admission for preeclampsia and subsequent full-term delivery 0 2
Admission for gestational hypertension and subsequent full-term delivery 0 1
Admission for fetal growth restriction and subsequent preterm delivery 1 2
Preterm birth
Admission for preterm prelabor amniorrhexis 4 6
Admission for cervical cerclage for short cervix 1 1
Admission for preterm labor, with subsequent full-term delivery 1 1
Spontaneous early preterm birth 1 2
Vaginal bleeding
Admission for vaginal bleeding prepartum 0 5
*  None of these serious adverse events was considered by the investigators to be associated with metformin or placebo.
Table 3. Serious Adverse Events among Trial Participants.*
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ternal gestational weight gain, the rate of pre-
eclampsia, or the rate of adverse perinatal events. 
In our study, all racial groups were included so 
that the results would potentially be applicable to 
the general population. We also used a BMI cut-
off point of 35 rather than 30 because the inci-
dence of adverse pregnancy outcomes is much 
higher when the mother’s BMI is more than 35 
than when it is more than 30; the cutoff point 
of 35 enabled the study to have adequate power 
with a smaller sample size.10 Finally, we used a 
3.0-g dose of metformin, as compared with the 
2.5-g dose used in the EMPOWaR trial, to avoid 
potential criticisms, in the event of no effect, that 
the dose was inadequate, particularly in women 
with a very high BMI.
The EMPOWaR trial had 15 participating cen-
ters; our study had only 3 participating centers, 
which allowed closer supervision of the study and 
direct contact with most patients by a small 
group of researchers. This difference may have 
contributed to the higher rate of eligible women 
who agreed to participate and remain in the trial 
(47% [400 of 844 women] in our study vs. 13% 
[443 of 3329 women] in the EMPOWaR trial). 
Similarly, adherence to the study regimen was 
higher in our study, in which it was estimated that 
nearly 80% of women consumed at least 50% of 
the total number of tablets prescribed. In the EM-
POWaR trial, women were considered to have ad-
hered to the study regimen if they took a mini-
mum of one tablet of 500 g for at least 29% of the 
days between randomization and delivery; only 
67% of women fulfilled these criteria.
The failure of the EMPOWaR trial to show 
that the use of metformin was associated with 
less gestational weight gain and a lower incidence 
of preeclampsia than were seen with placebo — 
findings that were observed in our study — may 
be the consequence of lower adherence to an ad-
equate dose of medication. In our study, nearly 
66% of the women in the metformin group took 
a minimum dose of 2.5 g for at least 50% of the 
days between randomization and delivery. In the 
EMPOWaR trial, 2.5 g of metformin was taken for 
only 38% of the days between randomization and 
delivery in the group of patients receiving this 
dose, but the proportion of patients who were in 
this dose subgroup was not specified.
In conclusion, in pregnant obese women with-
out diabetes mellitus, prophylactic therapy with a 
daily dose of 3.0 g of metformin from 12 to 18 
weeks of gestation until delivery was associated 
with less maternal gestational weight gain than 
that observed with placebo but not with a lower 
median neonatal birth weight.
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